Novo Nordisk A/S – Reduction of the share capital
April 24 2024 - 8:48AM
Novo Nordisk A/S – Reduction of the share capital
Bagsværd, Denmark, 24 April 2024 – At Novo
Nordisk’s Annual General Meeting on 21 March 2024, it was decided
to reduce the company’s B share capital from DKK 343,512,800 to DKK
339,012,800 by cancellation of part of the company’s portfolio of
own B shares equal to a nominal value of DKK 4,500,000 divided into
45,000,000 B shares of DKK 0.10 each.
Today, Novo Nordisk has registered the implementation of the
reduction of the share capital with the Danish Business Authority
and cancelled B shares at a nominal value of DKK 4,500,000.
After the reduction of the share capital, the company’s share
capital is nominally DKK 446,500,000, which is divided into an A
share capital of nominally DKK 107,487,200 and a B share capital of
nominally DKK 339,012,800.
The reduction of the share capital will not affect Novo
Nordisk’s share repurchase programme, which will continue as
previously announced.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 63,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contact for further information
Media: |
|
Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Liz
Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com |
Investors: |
|
Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
Sina
Meyer +45 3079 6656azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259fptr@novonordisk.com |
Company announcement No 32 / 2024
- CA240424-reduction-of-share-capital
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
From May 2023 to May 2024